Lattice Biologics (TSXV:LBL.H) Retained Earnings : C$-13.36 Mil (As of Jun. 2021)

View and export this data going back to 1995. Start your Free Trial

What is Lattice Biologics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Lattice Biologics's retained earnings for the quarter that ended in Jun. 2021 was C$-13.36 Mil.

Lattice Biologics's quarterly retained earnings increased from Dec. 2020 (C$-23.28 Mil) to Mar. 2021 (C$-15.87 Mil) and increased from Mar. 2021 (C$-15.87 Mil) to Jun. 2021 (C$-13.36 Mil).

Lattice Biologics's annual retained earnings declined from Sep. 2018 (C$-20.09 Mil) to Sep. 2019 (C$-21.75 Mil) and declined from Sep. 2019 (C$-21.75 Mil) to Sep. 2020 (C$-23.69 Mil).

Lattice Biologics Retained Earnings Historical Data

The historical data trend for Lattice Biologics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lattice Biologics Retained Earnings Chart

Lattice Biologics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Sep16

Sep17

Sep18

Sep19

Sep20

Retained Earnings

Get a 7-Day Free Trial

-16.59

-17.42

-20.09

-21.75

-23.69

Lattice Biologics Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Retained Earnings	Get a 7-Day Free Trial															-23.95	-23.69	-23.28	-15.87	-13.36

Lattice Biologics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Lattice Biologics (TSXV:LBL.H) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Lattice Biologics (TSXV:LBL.H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lattice Biologics Ltd (TSXV:LBL.H) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

512 East Madison Avenue, Suite A1, Belgrade, MT, USA, 59714

Website

http://www.latticebiologics.com

Lattice Biologics Ltd is a biologic product manufacturing company. It manufactures and markets biologic products to domestic and international markets. The products of the company include ADM dermis, DBM Putty, Bone scaffold, and Others, of which key revenue is derived from Bone scaffold. The biologic products are used in various applications such as enhancing fusion in spine surgery, enhancing breast reconstruction post mastectomy for breast cancer patients, sports medicine applications, promotion of bone in foot and ankle surgery, promotion of skull healing following neurosurgery, and subchondral bone defect repair in knee and other joint surgeries. The company generates its revenue from operations principally carried in the United States of America.

Lattice Biologics (TSXV:LBL.H) Headlines

No Headlines